Rivière M, Tretiak R, Levinton C, Fitzsimon C, Leclerc C
Quintiles Canada Inc, Montreal, Quebec.
Can J Infect Dis. 1997 Sep;8(5):257-64. doi: 10.1155/1997/215175.
To evaluate the potential economic benefits of a program for a second routine dose of combined measles, mumps and rubella (MMR) vaccine, administered to children in Canada.
Both published and unpublished data from the United States and Canada were incorporated into a linear model. This information was supplemented with opinions on probability and resource use from interviews with a Canadian panel of physicians and practitioners. The province of Quebec was used as a model for resource use and costs.
Data were based on a vaccination program for Canadian children at 18 months, with an estimated annual birth cohort of 400,000. Further data were also collected for the lifetime costs of complications arising from these diseases or from vaccination, for both patients and family caregivers.
Outcomes were reviewed from the perspectives of a provincial ministry of health (direct medical costs) and of society (all direct and indirect medical and nonmedical costs).
It was estimated that a second dose of MMR vaccine administered at 18 months of age would prevent 9200 cases of measles, 6120 cases of mumps and 1960 cases of rubella, producing a savings of $6.34 for every dollar spent from the ministry of health perspective, and $3.25 from the societal perspective.
A routine second dose immunization with MMR vaccine would result in considerable cost savings in Canada.
评估为加拿大儿童接种第二剂麻疹、腮腺炎和风疹联合疫苗（MMR）计划的潜在经济效益。
将来自美国和加拿大已发表和未发表的数据纳入线性模型。通过对加拿大一组医生和从业者进行访谈，获取有关概率和资源使用的意见，对这些信息进行补充。以魁北克省作为资源使用和成本的模型。
数据基于针对18个月大加拿大儿童的疫苗接种计划，估计每年出生队列有40万。还收集了这些疾病或疫苗接种引发并发症的终身成本数据，涉及患者及家庭护理人员。
从省级卫生部（直接医疗成本）和社会（所有直接和间接医疗及非医疗成本）的角度审查结果。
据估计，在18个月大时接种第二剂MMR疫苗可预防9200例麻疹、6120例腮腺炎和1960例风疹，从卫生部角度看，每花费1美元可节省6.34美元，从社会角度看可节省3.25美元。
在加拿大，常规接种第二剂MMR疫苗将带来可观的成本节省。
